The Food and Drug Administration sent warning letters to dozens of drug companies this month, including popular telehealth firm Hims & Hers, demanding they correct “false or misleading claims” about some of their products, targeting the companies just days after President Donald Trump signed an order designed to clamp down on direct-to-consumer drug advertising.
Key Facts
The warning letters were sent to over 100 companies, taking aim at the “unlawful sale of unapproved and misbranded drugs” to consumers over the internet.
Hims & Hers was sent a letter regarding its compounded semaglutide products, which are popular diabetes and weight management drugs.
Shares of Hims & Hers dropped more than 6% on Tuesday afternoon, though the company’s stock is still up 11.7% this month.
Forbes has reached out to the FDA and Hims & Hers for comment.
